Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders
Authors:
- Atheir AbbasAAAtheir Abbas
- Bryan L RothBRBryan L Roth
Open Access
- 28 November 2008
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Pharmacotherapy
- Vol. 9 (18) , 3251-3259
Abstract
Background: Pimavanserin tartrate is the first 5-HT2A inverse agonist to enter clinical trials as a treatment for L-dopa-induced psychosis in Parkinson's disease and for augmentation of low-dose risperidone treatment in schizophrenia. Pimavanserin is also being evaluated as a possible anti-insomnia drug. Objective: To discuss the potential of pimavanserin to fill multiple therapeutic needs. Methods: The problems with currently approved antipsychotics and sleep agents are explored to highlight how pimavanserin might address some longstanding issues in the treatment of psychosis and insomnia. Results/conclusions: In Phase II clinical trials, pimavanserin seemed to be safe, well-tolerated and efficacious in treating L-dopa-induced psychosis without worsening motor symptoms. Pimavanserin also potentiated the therapeutic effects of low-dose risperidone, reduced haloperidol-induced akathisia, and increased slow-wave sleep in older individuals.Keywords
This publication has 43 references indexed in Scilit:
- Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United StatesCurrent Medical Research and Opinion, 2007
- The pipeline and future of drug development in schizophreniaMolecular Psychiatry, 2007
- Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophreniaNature Reviews Drug Discovery, 2004
- The Global Costs of SchizophreniaSchizophrenia Bulletin, 2004
- Dopamine D2 and D3 Receptor Occupancy in Normal Humans Treated with the Antipsychotic Drug Aripiprazole (OPC 14597) A Study Using Positron Emission Tomography and [11C]RacloprideNeuropsychopharmacology, 2002
- Patient Compliance with Drug Therapy in SchizophreniaPharmacoEconomics, 2000
- NMDA receptor hypofunction model of schizophreniaJournal of Psychiatric Research, 1999
- Positron Emission Tomography ofin-vivoBinding Characteristics of Atypical Antipsychotic DrugsThe British Journal of Psychiatry, 1996
- Clozapine—A serotonin antagonist?Pharmacology Biochemistry and Behavior, 1984
- Chronic clozapine treatment of rats down-regulates cortical 5-HT2 receptorsEuropean Journal of Pharmacology, 1983